52 results about "Prokaryote" patented technology

The invention discloses a biological complex trait key gene identification method, device and equipment and a medium, and the method comprises the following steps: obtaining biological reference genome data, and carrying out orthologous gene class group division on a protein sequence coded by the biological reference genome data; determining a characteristic value data set according to the number of the subgroup sequence and the gene number of the subgroup sequence obtained after division; obtaining each piece of biological phenotype data; utilizing a machine algorithm model to construct a phenotype matrix according to the biological phenotype data and the characteristic value data set so as to train a phenotype prediction model, and determining the influence weight of each subgroup sequence on the biological phenotype according to the phenotype prediction model; and according to each influence weight, determining a key gene for regulating and controlling the biological complexity. The method provided by the invention can realize more accurate, efficient and comprehensive identification of key genes of prokaryotes and high biological complexity characters.

The invention discloses an intestinal flora marker related to juvenile depression, a product and application of the intestinal flora marker. The intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of the prokaryotic streptococcus parahaemolyticus, the streptococcus salivarius, the Alistipep and the Lacnospiraceae, the prokaryotic streptococcus parahaemolyticus, the Streptococcus salivarius, the Alistipep and the Lacnospiraceae. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal flora marker. The invention provides a product for diagnosing juvenile depression and a computer program product related to the juvenile depression. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of depression of teenagers, and provides a new tool for clinical diagnosis.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

Described in several example embodiments herein are engineered programmable pattern recognition compositions and uses thereof. In an embodiment, the engineered protein contains an NTPase of a Signal Transduction ATPases with Numerous-associated Domains (STAND) superfamily (STAND NTPase), comprising a pathogen-associated molecular pattern (PAMP) recognition activity, wherein the STAND NTPase and the PAMP recognition activity are derived from the same or different prokaryotes.

Methods for producing organosulfur compounds from a prokaryotic cell comprising enzymes involved in the production of cysteamine, hypotaurine, and taurine. Said prokaryote may comprise a vanin selected from vanin-1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and / or a flavin-containing monooxygenase 1 (fmo1). Methods include the expression of organosulfur compounds in Corynebacterium glutamicum with incubation conditions to promote compound production.

Novel combinations of cysteine-rich insecticidal proteins (CRIPs) and insecticides (IAs), such as chemicals, molecules, nucleotides, polynucleotides, peptides, polypeptides, proteins, toxins, toxic substances, poisons, insecticides, pesticides, organic compounds, inorganic compounds, prokaryotes or eukaryotes (and substances produced from such prokaryotes or eukaryotes), are described and claimed for the control and / or eradication of pests. [Solution] Novel insecticide combinations, compositions, and methods for using them are provided. The present invention relates to a combination of a cysteine-rich insecticide peptide (CRIP) and an insecticide (IA). The present invention also describes the use of the combination and composition for controlling insects. This specification describes the gene encoding CRIP, compositions and combinations containing CRIP and IA, and methods useful for controlling pests using them.

The invention provides an anti-tumor peptide modified bacterial outer membrane vesicle and a preparation method thereof, and relates to the technical field of engineering bacterial outer membrane vesicles. According to the invention, a recombinant plasmid capable of expressing a ClyA-A25 fusion protein in a prokaryote is designed and constructed, and the engineering bacterium outer membrane vesicle W-A25OMV modified by the anti-tumor peptide A25 is successfully prepared by using the recombinant plasmid. The W-A25OMV retains the basic structure of bacterial outer membrane vesicles, enhances the anti-tumor biological activity of A25 peptide, has good stability, shows a remarkable inhibition effect on invasion and migration of tumor cells, can effectively promote apoptosis of the tumor cells, and has development and application potential as an anti-tumor drug.

The application discloses a novel lactoferrin inducible soluble expression system and a construction method thereof, and belongs to the technical field of biotechnology and genetic engineering, and the specific scheme is that human lactoferrin (LF) is expressed by probiotic Escherichia coli Nissle1917, the protein is purified after the expression position is determined, and anti-inflammatory activity is determined. The LF expression system constructed by the application provides a construction method of a prokaryotic expression stable human lactoferrin expression vector, the vector is introduced into probiotic Escherichia coli Nissle1917, soluble target recombinant human lactoferrin is obtained after induction fermentation expression, two-step purification and identification, and the application has the characteristics of high safety, low cost, easy operation and the like.

A genetically modified prokaryotic cell to express enzymes involved in the production of taurine. Said prokaryote comprises a vanin selected from: vanin- 1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and a flavin-containing monooxygenase 1 (fmol), in addition to either the addition, alteration, or deletion of at least one gene involved in taurine synthesis or transport.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of an N protein polyclonal antibody of a horse coronavirus. The polyclonal antibody is prepared by truncation expression of the horse coronavirus N protein, and a material is provided for research on inhibition of host innate immune mechanism by the horse coronavirus N protein. Prokaryotic expression is carried out on the N protein of the equine coronavirus, the polyclonal antibody is prepared, and a method and a material are provided for molecular research and mechanism research of the equine coronavirus. According to the invention, in combination with bioinformatics analysis of an N protein of the horse coronavirus, a pGEX-6p-N3 recombinant plasmid is constructed, and prokaryotic expression is carried out, so that a purified recombinant protein is obtained. After a mouse is immunized by the recombinant protein, a polyclonal antibody is obtained, an indirect ELISA method detects that the polyclonal antibody has good titer, Western Blot detection has good reactivity, and the polyclonal antibody can be applied to an indirect immunofluorescence test.

The invention relates to a method for improving the prokaryotic expression quantity of CRISPR-dCas9 (clustered regularly interspaced short palindromic repeats) protein. Specifically, the invention relates to a method for improving the expression level of dCas9 protein in a prokaryotic cell, and a leucine zipper gene sequence and a dCas9 gene sequence are connected and introduced into the prokaryotic cell. According to the method, the high-purity and high-concentration dCas9 protein can be obtained, the expression quantity of the dCas9 protein is remarkably higher than that of a common method using maltose binding protein (MBP) as a fusion molecular chaperone, the obtained dCas9-lzip fusion protein still has the capability of being normally combined with DNA in a targeted manner under the guidance of sgRNA, and the function of dCas9 is not influenced by connection of a lzip sequence.

Nucleic acids (e.g., messenger RNA) encoding at least one antigen prokaryotic polypeptide linked to one or both of a viral secretion signal peptide and a transmembrane domain are provided herein. Also provided is a method of vaccinating against prokaryotic infection with the nucleic acids described herein.

This invention, belonging to the field of bioinformatics, discloses a cross-species prediction method for peptide-encoding sequence-dependent open-type recurrent (sORF) proteins. The method integrates protein-encoding DNA sequences from human and mouse sORF databases, Arabidopsis thaliana from the TAIR database, and some prokaryotes from the NCBI database. Positive and negative samples corresponding to each species are constructed using data filtering and negative sample generation strategies. Sequence features are extracted and the training set is screened using maximum relevance minimum redundancy and incremental selection methods to obtain the optimal feature sets corresponding to different methods and construct a peptide-encoding sORF prediction model. Parameters are optimized using a greedy grid search method to construct the optimal prediction model based on a support vector machine. The prediction model is evaluated using sensitivity, specificity, accuracy, and the Matthews correlation coefficient. This method facilitates the classification and identification of peptide-encoding sORFs and is of great significance for the study of peptide-encoding sORFs and gene annotation.

The invention relates to the technical field of molecular biology, in particular to Argonaute protein derived from normal-temperature prokaryotes and gene editing application of the Argonaute protein. The amino acid sequence of the Argonaute protein is as shown in SEQ ID No.1, or the Argonaute protein has more than 90%, more than 95%, more than 98%, preferably more than 99% of identity with the sequence as shown in SEQ ID No.1, has the same function and comes from normal-temperature prokaryotes. The prokaryote Ago protein and PLD nuclease AgaP coupled with the prokaryote Ago protein are used for endowing a host with a virus defense function for the first time, and a strain with antiviral capacity can be constructed; furthermore, on the basis of the function of the Ago protein, the NpAgo can be used for remarkably improving the gene editing efficiency in escherichia coli, and the practical application of bacterial gene editing is effectively improved.

The invention relates to a modular culture system for growing prokaryotic and / or eukaryotic organisms using a nutrient solution (N) for the organisms, wherein the culture system comprises a series of culture modules (100) for receiving the organisms, which culture modules are interconnected to conduct the nutrient solution (N), and an extraction module (200), connected to one of the culture modules (100) for conducting the nutrient solution (N), for the controlled extraction of the nutrient solution (N) from the culture module (100).Each culture module (100) comprises: an outer container (110) through which the nutrient solution (N) flows in a flow direction (S); an inner container (120), located at least partially within the outer container (110), for receiving the organisms; and several connection devices (130) for connecting the outer container (110) to the outer container (110) of an additional culture module (100) and / or to the extraction module (200) for conveying the nutrient solution (N). The inner container (120) is permeable to the nutrient solution (N), and a nutrient chamber (115), through which the nutrient solution (N) flows, is located between the outer container (110) and the inner container (120). The extraction module (200) comprises an extraction control device (240) for controlling the flow of the nutrient solution (N) extracted from the cultivation module (100) by means of the extraction module (200).

The application belongs to the field of animal bacteriology and molecular biology technology, and relates to preparation of a hybridoma cell and application thereof. A monoclonal antibody is prepared through intracellular Lawsonia intracellularis outer membrane protein OmpA expressed by prokaryotes, and IFA, WB and blocking ELISA and other immunological detection methods for detecting or diagnosing Lawsonia intracellularis are established through the expressed intracellular Lawsonia intracellularis outer membrane protein OmpA and the prepared monoclonal antibody. The blocking ELISA for detecting serum antibodies of Lawsonia intracellularis can detect serum samples of suspected Lawsonia intracellularis infection from different species, and does not exist cross reaction with positive serum of common pig pathogens, has high sensitivity and specificity, is good in repeatability, and is suitable for high-throughput detection of serum samples.

The present invention discloses a recombinant type VII collagen protein, Pro.C7, whose amino acid sequence is shown in any one of SEQ ID NOs. 1-8. Also disclosed are its encoding gene, expression vector, host bacteria, preparation method, and application. The present invention designs recombinant human type VII collagen based on a partial sequence of human type VII collagen. The protein is expressed in prokaryotes, and the expression system is mature. The purified protein has been experimentally verified to be non-cytotoxic. By organizing laminin, it promotes fibroblast migration and cytokine secretion, participates in skin damage and repair, and can be used as a biomaterial in cosmetic products, among other applications.

Rhizobial infection is the key process for initiating symbiotic nitrogen-fixing root nodules in legumes, which requires specific recognition of signal molecules produced by the bacteria and their hosts. Here, it is established that rhizobial tRNA-derived small RNA fragments (tRFs) are crucial signal molecules modulating host nodulation, which uncovers a bacterial small RNA-mediated mechanism for prokaryote-eukaryote interaction. Transgenic plants are also provided that express a construct encoding rhizobial-derived tRNA, which is subsequently cleaved to produce artificial tRFs. Constructs and methods of producing the same are also provided, as well as modifications for repressing a mechanism for the negative regulation of nodulation present within plants.

This invention relates to the field of genetic engineering technology, and more particularly to a method for prokaryotic expression of antimicrobial peptides. The method provided by this invention involves inserting an antimicrobial peptide gene into the 3' or 5' end of a fusion tag gene for fusion expression. The protein, forming numerous inclusion bodies, eliminates the original antimicrobial activity of the antimicrobial peptide, thus preventing the killing of host bacteria. The method provided by this invention allows for the large-scale preparation of antimicrobial peptides in a prokaryotic expression system. The method is simple and easy to implement, and the obtained antimicrobial peptides exhibit significant in vitro antibacterial effects after enzymatic digestion and purification.

The application provides a human-derived genetically engineered antibody with targeted simulation of Bt Cry1C toxin structure and insecticidal function and a high-activity mutant of the human-derived genetically engineered antibody, nucleotide sequences and amino acid sequences of the human-derived genetically engineered antibody are respectively shown as SEQ IN NO. 1 and SEQ IN NO. 2, nucleotide sequences and amino acid sequences of the mutant are respectively shown as SEQ IN NO. 3 and SEQ IN NO. 4; after the antibody and the mutant are expressed in prokaryotes, the LD50 of corresponding proteins to Plutella xylostella larvae is respectively 38.9% and 46.8% of the original Bt Cry1C toxin, the LD50 of corresponding proteins to cotton bollworm larvae is respectively 32.9% and 37.4% of the original Bt Cry1C toxin; the two can be respectively used as coating antigens in an IC-ELISA detection method to detect Bt Cry1C toxin with high sensitivity; the antibody and the mutant can be used as antigen analogue materials to replace the structure of Bt Cry1C toxin, not only can be used as new protein insect-resistant materials to have potential application value in green control of agricultural pests, but also can be used for detection of Bt Cry1C toxin residues in the environment and food samples, and have wide application value.

The invention discloses a method for specifically separating eukaryotic cells from prokaryotic cells in various environments. The invention provides a concanavalin A and magnetic bead complex. The concanavalin A and magnetic bead complex is a complex formed by connecting concanavalin A and magnetic beads, the invention also provides a method for separating eukaryotic cells and prokaryotic cells, which comprises the following steps: adding the concanavalin A and magnetic bead complex into a cell resuspension to be separated, and incubating; and separating the eukaryote cells adsorbed by the magnetic beads from the prokaryote cells not adsorbed by the magnetic beads by using a magnetic frame. The raw materials such as the streptavidin magnetic beads and the concanavalin A involved in the method are low in price and simple to prepare; magnetic separation is utilized, and operation is simple and fast; the separation effect is good.

The present invention relates to the field of in vitro transcription, and provides a 5'UTR element. The 5'UTR element has a nucleotide sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 12. By providing a 5'UTR sequence, the present invention solves the problem of a prokaryotic 5'UTR sequence being unbale to simultaneously achieve high mRNA expression efficiency and high capping efficiency in in vitro synthesis of mRNA.

The disclosure provides methods to assemble genomes of eukaryotic or prokaryotic organisms. The disclosure further provides methods for haplotype phasing and meta-genomics assemblies.

The invention discloses a chromoprotein mutant and application thereof, and relates to the technical field of biology. According to the invention, a plurality of chromoprotein mutants with different colors and color depths are generated through point mutation on the basis of purple chromoprotein of Gfast Purple derived from coral, and the chromoprotein mutants are obvious in color generation, have no obvious toxicity to escherichia coli, are suitable for expression in prokaryotic and eukaryotic organisms, are high in stability, and can be used for preparing the chromoprotein mutants with different colors and color depths. The method has good potential application value in the fields of biological color regulation and control, cell marking, natural pigment additives and the like.

The invention discloses preparation and application of oligopeptide immune carrier protein, and belongs to the technical field of biology. The method comprises the following steps: fusing a gene sequence for coding oligopeptide and a gene sequence for coding ferritin through a chemical method by utilizing the characteristics that oligopeptide molecules are small in mass and ferritin is self-assembled to form a polymer, and then cloning the fused gene into a prokaryotic biological carrier for expression; the recombinant protein is purified by using an expression system which is not limited to prokaryotes such as escherichia coli and eukaryotes. The protein has the advantages of low preparation cost, strong immunogenicity and the like, and lays a foundation for obtaining a high-affinity anti-oligopeptide nano antibody.

The invention discloses a recombinant human colloidal fiber acidic protein and a preparation method thereof, and relates to the technical field of biology. The invention discloses a preparation method of recombinant human colloidal fibrillary acidic protein, which comprises the following steps: acquiring a protein sequence of human colloidal fibrillary acidic protein from NCBI (National Center of Biotechnology Information), artificially optimizing and synthesizing a colloidal fibrillary acidic protein coding gene according to the codon bias characteristic of escherichia coli, and further constructing an expression vector of the human colloidal fibrillary acidic protein. And then purifying the expression product to obtain the recombinant protein with relatively high purity. The expressed and purified recombinant human-derived glial fibrillary acidic protein can be well combined with a specific antibody, and can meet the detection requirements. According to the invention, the gene sequence of the prokaryotically expressed recombinant human glial fibrillary acidic protein is optimized, and a matched prokaryotic expression system is established, so that the target protein is in soluble expression, and the natural structure and functional integrity of the protein are retained.

The invention discloses a recombinant VII type collagen Pro.C7. The amino acid sequence of the recombinant VII type collagen Pro.C7 is shown as any one of SEQ ID NO.1-8. The invention also discloses a coding gene, an expression vector, host bacteria, a preparation method and application of the gene. The recombinant human VII type collagen is designed on the basis of a part of sequences in the human VII type collagen, prokaryote expression, mature expression system and purified protein have no cytotoxicity through experimental verification, fibrocyte migration and cytokine secretion are promoted through tissue laminin, and the human VII type collagen participates in skin injury and repair, so that the human VII type collagen can be used for repairing skin. The material can be applied to beauty products and the like as a biological material.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

According to the eukaryote level gene transfer identification method and device, the storage medium and the computer equipment provided by the invention, after the target protein sequence of the high-quality genome of the target eukaryote is extracted, the target protein sequence can be compared with the protein sequence in the NR database; screening the protein sequences in the comparison result according to a preset screening condition to obtain a plurality of candidate sequences corresponding to the target protein sequence and a donor sequence corresponding to each candidate sequence, and then performing multi-sequence comparison on each candidate sequence and the corresponding donor sequence, and constructing a corresponding gene topological structure according to a multi-sequence comparison result of each candidate sequence, and determining a biological group in which each gene topological structure is located, so that the candidate sequence, in which the gene topological structure is located in the prokaryotic biological group, in each candidate sequence can be used as a gene sequence from prokaryotic horizontal transfer. And according to a gene topological structure, automatically eliminating non-conforming candidate sequences.

The application provides a genetically engineered bacterium for producing recovery promoting factor Rpf and application thereof, relates to the technical field of bioengineering, and belongs to prokaryotes. The nucleotide sequence of the genetically engineered bacterium is shown in SEQ ID NO. 1. The sequence is obtained by codon mutation and DNA sequence optimization of a wild-type bacterium recovery promoting factor of Micrococcus luteus in an original nucleotide sequence, and the optimized nucleotide sequence is named Delta Rpf. The original nucleotide sequence is shown in SEQ ID NO. 2. The purity of the Delta Rpf recombinant protein of the application can reach 93 %, which is much higher than the purity of the protein extracted by the prior art. The enzymatic activity of the Delta Rpf recombinant protein prepared by the genetically engineered bacterium constructed by the application is significantly higher than the enzymatic activity of the unmutated Rpf protein.